Recursion Pharmaceuticals, Inc.

Recursion Pharmaceuticals is a clinical-stage biotechnology company that integrates technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company operates in the United States and the United Kingdom. Its pipeline includes several drug candidates: REC-4881 for familial adenomatous polyposis (Phase 1b/2), REC-617 for advanced solid tumors (Phase 1/2), REC-1245 for biomarker-enriched solid tumors and lymphoma (Phase 1/2), REC-3565 for relapsed or refractory B-cell malignancies (Phase 1/2), and REC-4539, a potential best-in-class LSD1 inhibitor for solid tumors and hematology oncology. Preclinical candidates include REC-7735 for HR+ breast cancer and REC-102 for hypophosphatasia.

Recursion Pharmaceuticals is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol RXRX. The company's shares are traded in U.S. dollars (USD). As a U.S.-based company headquartered in Salt Lake City, Utah, its primary listing is on a major U.S. exchange, providing liquidity and accessibility to investors globally.

Recursion Pharmaceuticals operates in the Healthcare sector, specifically within the Biotechnology industry. As a clinical-stage biotechnology company, it focuses on drug discovery and development, leveraging advanced technologies to decode biology and chemistry. The company's work involves creating treatments for various diseases, including cancers and genetic disorders, which places it firmly in the biotech subsector of healthcare.

Recursion Pharmaceuticals is headquartered in Salt Lake City, Utah, United States. The company was incorporated in 2013. It serves markets in the United States and the United Kingdom, as indicated by its operations in both countries. Its collaborations with major pharmaceutical companies like Roche & Genentech, Sanofi, Bayer AG, Tempus, and Takeda Pharmaceutical Company Limited further extend its reach in the global biotech landscape.

Recursion Pharmaceuticals has a robust pipeline of drug candidates targeting various diseases. Key clinical-stage candidates include REC-4881 (Phase 1b/2 for familial adenomatous polyposis), REC-617 (Phase 1/2 for advanced solid tumors), REC-1245 (Phase 1/2 for biomarker-enriched solid tumors and lymphoma), REC-3565 (Phase 1/2 for relapsed or refractory B-cell malignancies), and REC-4539 (a reversible, CNS penetrant, orally bioavailable LSD1 inhibitor for solid tumors and hematology oncology). Preclinical candidates include REC-7735 for HR+ breast cancer and REC-102 for hypophosphatasia. The company also has collaborations with Roche & Genentech, Sanofi, Bayer AG, Tempus, and Takeda.